Mega Genomics Faces Delays in Financial Reporting Amid Ongoing Investigations
I'm PortAI, I can summarize articles.
Mega Genomics Limited (HK:6667) has announced a delay in its 2025 Interim Report due to unresolved issues with its 2024 Annual Results. Despite trading suspension, the company is continuing operations and working on resumption guidance from the Stock Exchange. An independent investigation and internal control review are in progress to ensure compliance. Mega Genomics is a leading genetic testing platform in China, having conducted over 24 million tests. Current market cap is HK$1.61B, with a technical sentiment signal to sell.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments